Treatment of Influenza in Immunocompromising Conditions and Immunosuppression

Patients with immunocompromising conditions or who are immunosuppressed face a heightened risk of complications from influenza. This protocol addresses the specific management considerations that apply when influenza occurs in this population.

Clinical Scenario

This protocol applies to patients with an immunocompromising condition or immunosuppression who develop influenza. Immunocompromised patients are at high risk of complications from influenza — including progression to severe lower respiratory tract disease — and require prompt antiviral treatment tailored to their clinical situation.

Treatment Approach (Partial Overview)

Oral antiviral therapy is the cornerstone of management. In immunocompromised patients, the duration of treatment is a critical factor: a course longer than the standard regimen is often warranted, particularly when the disease course is severe or viral RNA remains detectable. The complete agent selection, duration guidance, and management algorithm are available in the full protocol.

Treatment Goals

Clearance of influenza viral RNA from the respiratory tract
Resolution of influenza illness

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciy866

Outpatients who are at high risk of complications from influenza, including those with chronic medical conditions and immunocompromised patients (A-II).

Clinicians can consider longer duration of antiviral treatment for patients with a documented or suspected immunocompromising condition or patients requiring hospitalization for severe lower respiratory tract disease (especially pneumonia or acute respiratory distress syndrome [ARDS]), as influenza viral replication is often protracted (C-III).

There are limited data to define the optimal duration of therapy for influenza in immunocompromised patients, but retrospectively collected data suggest that treatment can safely extend to 10 days or longer.

Rebound in influenza viral replication has been observed in some patients treated for 5 days, and longer duration of treatment is advisable if the disease course is severe and influenza viral RNA remains detectable.

View source ↗